Nadia Harbeck

Trials

Studies that name Nadia Harbeck as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT07242352 · Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

  Women's Cancer Study Group GmbH · recruiting · Breast Cancer, HR+/HER2- Breast Cancer · principal investigator
• Ph3
  NCT07178730 · NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

  Women's Cancer Study Group GmbH · not yet recruiting · Breast Cancer, Triple-negative Breast Cancer · principal investigator
• Ph3
  NCT06081244 · NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

  Women's Cancer Study Group GmbH · recruiting · Triple Negative Breast Cancer · principal investigator
• N/A
  NCT05792150 · PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

  Women's Cancer Study Group GmbH · recruiting · Female Breast Cancer · principal investigator
• Ph2
  NCT05704829 · NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

  Women's Cancer Study Group GmbH · recruiting · HER2-positive Early Breast Cancer · principal investigator
• Ph3
  NCT04739761 · A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

  AstraZeneca · active not recruiting · Breast Cancer · principal investigator
• Ph3
  NCT04055493 · Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

  Women's Cancer Study Group GmbH · active not recruiting · Breast Cancer Female · principal investigator
• N/A
  NCT02269813 · PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

  Women's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
• Ph3
  NCT02214381 · A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

  Women's Cancer Study Group GmbH · completed · Early Primary Breast Cancer · principal investigator
• N/A
  NCT01974856 · A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay

  NanoString Technologies, Inc. · completed · Breast Cancer · principal investigator
• Ph2
  NCT01817452 · A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol

  Women's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
• Ph2
  NCT01815242 · Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

  Women's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
• Ph2/Ph3
  NCT01781338 · Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

  Women's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
• Ph2/Ph3
  NCT01779206 · ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

  Women's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
• Ph2
  NCT01745965 · A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.

  Women's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
• Ph2
  NCT01690325 · Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

  Women's Cancer Study Group GmbH · terminated · Breast Cancer · principal investigator
• Ph3
  NCT01222052 · 6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients

  Martin-Luther-Universität Halle-Wittenberg · unknown · Breast Cancer · principal investigator
• Ph3
  NCT01049425 · Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

  Women's Cancer Study Group GmbH · completed · Primary Breast Cancer, Her2 Non-overexpressing · study chair
• Ph2
  NCT00615940 · Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

  Heidelberg Pharma AG · completed · Metastatic Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.